ACTUALITES

SEMINARS

  • CRCL/CLB Seminar

Two seminars will take place thi Friday 8th of December in the ONCORA meeting room :

  • 9.30 AM : we are pleased to welcome Pr. Jack Tuszynski from the University of Alberta (Canada). His lecture is entitled : "Accelerating and optimizing anti-cancer drugs and their combinations using in silico methodologies”.
  • 11.30 AM : we are pleased to welcome Dr. Jean-Christophe Marine from the VIB Laboratory for Molecular Cancer Biology, K.U.Leuven. The title of his lecture will be : "From new insights into melanoma biology to improved diagnostic and therapeutic strategies".

SCIENTIFIC EVENTS

  • 3rd International CRCL Symposium

The 3rd CRCL Symposium took place in 25th-27th September 2017 ! Many thanks to our speakers, participants and sponsors, for their presence and support.

More information on our website available 
here.

Enjoy the highlights of the CRCL Symposium 2017 with the official video:

CRCL SYMPOSIUM 2017 from C.R.C.L on Vimeo.

OTHER

  • A new International Associated Laboratory (LIA)


The CRCL team of Alain Puisieux "EMT and cancer cell plasticity"  sucessfully applied to an Inserm call to develop an International Associated Laboratory together with the group of Frederic Holland "Molecular mechanisms of tumor progression", from the Victorian Comprehensive Cancer Cancer, University of Melbourne, Australia.

LATEST PUBLICATIONS

  • Immature CML cells Implement a BMP Autocrine Loop to Escape TKI Treatment.


This study has been performed by the "
BMP, tumoral niche and resistance" team, directed by Véronique Maguer-Satta.

The BCR-ABL specific Tyrosine Kinase Inhibitors (TKI) changed the outcome of Chronic Myeloid Leukemia (CML), turning a life-threatening disease into a chronic illness. However, TKI are not yet curative, since most patients retain leukemic stem cells (LSC) and their progenitors in bone marrow and relapse following treatment cessation.
> MORE INFORMATION
PubMed access

  • Evidence for rRNA 2′-O-methylation plasticity: Control of intrinsic translational capabilities of hu


This study has been performed by the "Nuclear domains and pathologies" team, directed by Jean-Jacques Diaz.
Ribosomal RNAs (rRNAs) are main effectors of messenger RNA (mRNA) decoding, peptide-bond formation, and ribosome dynamics during translation. Ribose 2′-O-methylation (2′-O-Me) is the most abundant rRNA chemical modification, and displays a complex pattern in rRNA. 2′-O-Me was shown to be essential for accurate and efficient protein synthesis in eukaryotic cells.

> MORE INFORMATION
doi: 10.1073/pnas.1707674114

JOB OPPORTUNITIES

  • Décembre 2017

L'équipe Anticorps Anticancer, dirigée par le Pr Charles Dumontet, recherche un post-doctorant pour un projet "d'évaluation préclinique d'un nouvel agent immunostimulant à visée thérapeutique dans les modèles de cancérologie". 
Plus d'informations

  • Octobre 2017

We are currently looking for postdoctoral researcher to join the “Activin Tumor Signaling” group of the Signaling, metabolism and tumor progression team headed by Ruth Rimokh/Germain Gillet at the Cancer Research Centre of Lyon (CRCL, France; http://www.crcl.fr). This team is part of the CRCL that will provide an excellent research environment including core facilities, support services as well as an international stimulating environment.
More information here

  • Aout 2017

Chef de Projet RHU cirB-RNA.
Le programme du RHU cirB-RNA s’intègre dans la dynamique de recherche autour du virus de l’hépatite B, la détection et la prise en charge de la maladie, coordonnée par les Professeurs Zoulim et Levrero.
Plus d'informations

CENTRE DE RECHERCHE EN CANCEROLOGIE DE LYON (CRCL)
UMR INSERM 1052 CNRS 5286 - CENTRE LEON BERARD
Copyright 2011. CRCL
SUIVEZ LES ACTUALITES
DU CRCL SUR TWITTER :
http://www.putainporno.com/videos-porno/porno-francais/ porno http://www.belloporno.com/channels/14/gay/page1.html